Strategies and Perspectives in Treatment of Respiratory Infections

Hj, Neijens

doi:10.1111/apa.1989.78.s363.66

Cited by 4 publications

(1 citation statement)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They needed anti PA antibiotic treatment either because of chronic colonization with PA leading to systematic antibiotic treatment every 3-4 months [16] or because of signs of pulmonary exacerbation: change in volume, appearance and/or colour of sputum, increased respiratory rate or dyspnoea, progressive physical findings on chest auscultation, increased cough, deterioration of spirometric parameters, decreased appetite, loss of weight, asthenia, or fever [9,10,15]. The diagnosis of CF was confirmed by at least two abnormal sweat tests (sweat chloride > 60 mE@).…”

Section: Patientsmentioning

confidence: 99%

Tolerance, pharmacokinetics and efficacy of once daily amikacin for treatment of Pseudomonas aeruginosa pulmonary exacerbations in cystic fibrosis patients

Vic¹,

Ategbo²,

Turck

et al. 1996

Eur J Pediatr

View full text Add to dashboard Cite

show abstract

Section: Patientsmentioning

confidence: 99%

Tolerance, pharmacokinetics and efficacy of once daily amikacin for treatment of Pseudomonas aeruginosa pulmonary exacerbations in cystic fibrosis patients

Vic¹,

Ategbo²,

Turck

et al. 1996

Eur J Pediatr

View full text Add to dashboard Cite

show abstract

Auxotrophy ofPseudomonas aeruginosain cystic fibrosis

Taylor

Hodson

Pitt

1992

FEMS Microbiology Letters

View full text Add to dashboard Cite

Seventy‐four of 403 (18.4%) sputum isolates of Pseudomonas aeruginosa from 49 of 136 (36.0%) adults with cystic fibrosis (CF) were auxotrophic mutants. Two of 11 (18.2%) isolates of P. aeruginosa taken from patients with non‐CF bronchiectasis were also auxotrophic. All 99 strains taken from non‐bronchiectatic sources were prototrophic. Forty‐six of 55 (83.6%) CF auxotrophs required one or more of 36 growth factors tested; the requirements for the remaining 9 isolates were not identified. Methionine was the sole factor required by 17 of 22 (77.3%) isolated which depended on a single factor. We conclude that auxotrophy is a feature of P. aeruginosa infection in cystic fibrosis.

show abstract

Efficacy, tolerance, and pharmacokinetics of once daily tobramycin for pseudomonas exacerbations in cystic fibrosis

Vic¹,

Ategbo²,

Turck

et al. 1998

Archives of Disease in Childhood

View full text Add to dashboard Cite

Objective-To compare once daily with thrice daily tobramycin for treatment of Pseudomonas aeruginosa infection in patients with cystic fibrosis. Design-22 patients with cystic fibrosis, mean (SD) age 11 (3.4) years (range 5.6-19.3), with pulmonary pseudomonas exacerbations were randomly assigned to receive a 14 day course of tobramycin (15 mg/kg/day) either in three infusions (group A) (n = 10) or a single daily infusion (group B) (n = 12), combined with ceftazidime (200 mg/kg/day as three intravenous injections). EYcacy was assessed by comparison of pulmonary, nutritional, and inflammatory indices on days 1 and 14. Cochlear and renal tolerance were assessed on days 1 and 14. Tobramycin concentration was measured in serum and sputum 1, 2, 3, 4, 8, and 24 hours after the start of the infusion. Analysis was by non-parametric Wilcoxon test. Results-Variables improving (p < 0.05) in both groups A and B were, respectively: weight/height (+4% and +3.1%), plasma prealbumin (+66 and +63 mg/l), forced vital capacity (FVC) (+14% and +11%), forced expiratory volume in one second (+15% and +14%), and forced expiratory flow between 25% and 75% of FVC (+13% and +21%). Improvement was not significantly diVerent between groups. Renal and cochlear indices remained within the normal range. Serum peak concentration of tobramycin on day 1 was 13.2 (7.1) mg/l in group A and 42.5 (11.2) mg/l in group B (p < 0.001); serum trough was 1.1 (0.8) mg/l in group A and 0.3 (0.2) mg/l in group B (p < 0.01). Tobramycin concentrations in sputum were two to three times higher in group B than group A. Conclusions-Once daily tobramycin combined with three injections of ceftazidime is safe and eVective for the treatment of pseudomonas exacerbations in cystic fibrosis patients. (Arch Dis Child 1998;78:536-539)

show abstract

Strategies and Perspectives in Treatment of Respiratory Infections

Cited by 4 publications

References 37 publications

Tolerance, pharmacokinetics and efficacy of once daily amikacin for treatment of Pseudomonas aeruginosa pulmonary exacerbations in cystic fibrosis patients

Tolerance, pharmacokinetics and efficacy of once daily amikacin for treatment of Pseudomonas aeruginosa pulmonary exacerbations in cystic fibrosis patients

Auxotrophy ofPseudomonas aeruginosain cystic fibrosis

Efficacy, tolerance, and pharmacokinetics of once daily tobramycin for pseudomonas exacerbations in cystic fibrosis

Contact Info

Product

Resources

About